Biophysics

Clarametyx Biosciences Appoints Renowned Experts to Augment Strategic and Scientific Advisory Boards

Retrieved on: 
tisdag, maj 28, 2024
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Patient, Biogen, Shionogi, Annamalai University, General partnership, Genentech, Biochemistry, Sarepta Therapeutics, Takeda Oncology, Biofilm, Flagship Pioneering, Palani, University, Therapy, Virginia Commonwealth University, Infection, MBA, Biophysics, MD, Takeda Pharmaceutical Company, Executive, Management

Dr. Palaniappan previously served as the Executive Vice President and Chief Technology Officer at Aruvant Sciences.

Key Points: 
  • Dr. Palaniappan previously served as the Executive Vice President and Chief Technology Officer at Aruvant Sciences.
  • His early career included leadership positions at Millennium Pharmaceuticals (acquired by Takeda), Biogen, Nexstar Pharmaceuticals (acquired by Gilead), and Par Pharmaceuticals.
  • He is currently a Managing Partner and Co-Founder of Trekk Venture Partners and serves on multiple public and private company boards.
  • Mr. Westberg received his MBA from the University of California, Berkeley and his BA from the University of California, San Diego.

EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member

Retrieved on: 
fredag, maj 10, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Other Health, Patient, Egle, Daiichi Sankyo, University, Immune system, Bristol Myers Squibb, Therapy, Drug development, GSK, Boehringer Ingelheim, Kyowa Kirin, ADC, MBA, MD, MedImmune, Biophysics, Cancer, CMO, Third Rock Ventures, Carnegie Mellon University, Drug discovery, Acquisition, Amgen, OrbiMed, Business development, Eli Lilly, Roche, Column, Immunotherapy, AstraZeneca, IO, Master of Science, Pharmaceutical industry

“We are excited to welcome Pejvack and John at Egle and to benefit from their strong experience.

Key Points: 
  • “We are excited to welcome Pejvack and John at Egle and to benefit from their strong experience.
  • The appointment of Dr Motlagh is critical for Egle, as the company is moving to clinical development of assets in oncology and auto-immunity.
  • Pejvack will impact the future development of the rich pipeline at Egle, based on the modulation of regulatory T cells.
  • As CMO, Pejvack will drive the clinical and medical strategy and development of our Company in the years to come.

Trinity University (San Antonio) Chemistry Professor Named as Fellow to American Association for Advancement of Science (AAAS)

Retrieved on: 
måndag, april 22, 2024
Education, University, Nanotechnology, Materials science, Protein, Mentorship, AAAS, American Chemical Society, Teaching, Heart, Trinity University, Publishing, Research, Biophysics, Engineering, Trinity, Chemistry, Student, SAN, Management

SAN ANTONIO, April 22, 2024 (GLOBE NEWSWIRE) -- Trinity University (San Antonio) announces chemistry professor Adam Urbach, Ph.D. , has been named a 2023 Fellow of the American Association for the Advancement of Science (AAAS)—one of the most prestigious recognitions possible for U.S. scientists.

Key Points: 
  • SAN ANTONIO, April 22, 2024 (GLOBE NEWSWIRE) -- Trinity University (San Antonio) announces chemistry professor Adam Urbach, Ph.D. , has been named a 2023 Fellow of the American Association for the Advancement of Science (AAAS)—one of the most prestigious recognitions possible for U.S. scientists.
  • His research program has developed rules for predictably interacting with proteins, leading to applications in drug formulation, biosensors, surface chemistry, materials science, and nanoscience.
  • As an AAAS fellow , Urbach is one of the only fellows in his class to hail from a liberal arts institution.
  • "After 20 years, I still love what I do, and I'm still fully committed to Trinity’s mission,” Urbach says.

Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors

Retrieved on: 
torsdag, april 18, 2024
Research, Infectious Diseases, FDA, Clinical Trials, Biotechnology, AIDS, Health, Science, Oncology, Biochemistry, Development, Bayer, HCV, Rutgers University, Biophysics, Communication, Baylor College of Medicine, Beneficial ownership, Infection, HIV, Name, Therapy, Harvard University, Publication, Research and development, Supervisory board, Drug development, Natural science, Doctor of Philosophy, University, Agriculture, Cancer, Bangladesh Technical Education Board, Gilead Sciences, Syntex, Patient, Pleasure, MBA, Annual general meeting, HBV, Kronos

Vir Biotechnology, Inc. (“Vir” or “the Company”, Nasdaq: VIR) today announced the nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors (the “Board”) at its upcoming annual meeting of stockholders on May 29, 2024 (the “Annual Meeting”).

Key Points: 
  • Vir Biotechnology, Inc. (“Vir” or “the Company”, Nasdaq: VIR) today announced the nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors (the “Board”) at its upcoming annual meeting of stockholders on May 29, 2024 (the “Annual Meeting”).
  • The nomination of the two new independent directors demonstrates Vir’s commitment to ongoing Board refreshment.
  • Marianne De Backer, M.Sc., Ph.D., MBA, Vir’s Chief Executive Officer, said: “We are incredibly excited about the prospect of adding such highly talented directors in Norbert and Ramy to the Board.
  • Previously, he served on the board of directors of Nimbus Therapeutics, a biotechnology company he helped found in 2009.

Helping to Diagnose and Treat Heart Disease, Tumors, and Other Conditions at the Intersection of Physics, Molecular Biology, and High-Performance Computing

Retrieved on: 
onsdag, april 24, 2024
CPU, Palace Hotel, Cancer, Biomedical sciences, Grace Murray Hopper Award, Corniche (Abu Dhabi), Applied physics, National academy, Infosys, Computer science, Disease, Cell, ACM, System, Hope, Oncology, Blood, Health, Heart, Friction, IEEE, Amanda Randles, Computer, Doctor of Philosophy, Research, ACM Prize in Computing, Biophysics, 3D, NSF, Duke University, Patient, APR, Physiology, Neoplasm, Cardiology, Harvard University, Technical, MIT, Medical imaging

NEW YORK, April 24, 2024 /PRNewswire/ -- ACM, the Association for Computing Machinery, has named Amanda Randles the recipient of the ACM Prize in Computing for groundbreaking contributions to computational health through innovative algorithms, tools, and high-performance computing methods for diagnosing and treating a variety of human diseases.

Key Points: 
  • Randles has developed computational tools to enable 3D blood flow simulations to diagnose and treat human diseases.
  • The ACM Prize in Computing recognizes early-to-mid-career computer scientists whose research contributions have fundamental impact and broad implications.
  • The award carries a prize of $250,000 from an endowment provided by Infosys Ltd., a global leader in next-generation digital services and consulting.
  • She also developed a new way to model the human heart, which allowed heart simulations for a large group of patients.

Bestqool Introduces Revolutionary Red Light Therapy for Home-Based Yogis: A New Horizon in Wellness and Yoga Practice

Retrieved on: 
fredag, mars 22, 2024
Well, AIMS, Glass, Yoga, COVID-19, Education, Link, Tissue, Research, Muscle fatigue, Joint, Student, Aesthetic Surgery Journal, Woman, Integrative Cancer Therapies, Patient satisfaction, Safety, Human factors and ergonomics, Red light, Martin, Biophysics, Health care

Well, the solution is simple - use Red Light Therapy alongside and make the most of your fitness experience in a more streamlined, healthier way.

Key Points: 
  • Well, the solution is simple - use Red Light Therapy alongside and make the most of your fitness experience in a more streamlined, healthier way.
  • It is recommended that all home-based yogis and yoga practitioners incorporate the use of Red Light Therapy at three stages of their lives, that is before, during, and after their yoga sessions.
  • Furthermore, Red Light therapy would work as a much-needed companion for your yoga sessions.
  • Bestqool 's hand-held Red Light Therapy devices are designed with the user in mind, offering ease of use, safety, and efficiency.

A-GAME Announces Appointment of Thomas Bond, MD, MS as Chief Medical Officer

Retrieved on: 
torsdag, mars 21, 2024
Doctor of Medicine, Health, Longevity, Bond, Drink, Intervention, Nutrition, Regenerative medicine, Physician, Education, Patient, Family medicine, University, Athlete, Exercise, Biophysics, Carolinas Medical Center, Sports medicine, Major League Baseball, LSU, Dentistry

ORLANDO, Fla., March 21, 2024 (GLOBE NEWSWIRE) -- A-GAME Beverages Inc. (“A-GAME”), creator of the “ultimate” hydration beverage, is pleased to announce the appointment of Dr. Thomas Bond as Chief Medical Officer.

Key Points: 
  • ORLANDO, Fla., March 21, 2024 (GLOBE NEWSWIRE) -- A-GAME Beverages Inc. (“A-GAME”), creator of the “ultimate” hydration beverage, is pleased to announce the appointment of Dr. Thomas Bond as Chief Medical Officer.
  • Bond will act as the first Chief Medical Officer for A-GAME Beverages and bring years and valuable experience of both clinical and sideline expertise in the field of Sports Medicine.
  • Dr.
  • Bond was recruited to LSU Medical Center in New Orleans as the Chief of Sports Medicine.

FundaMental Pharma Appoints Industry Veteran Dr. Lorenz Mayr as Non-Executive Director

Retrieved on: 
onsdag, mars 20, 2024
Medicines Discovery Catapult, Francis Crick Institute, AstraZeneca, Science, Drug discovery, Novartis, Fraunhofer, Patient, IPA, University, GE HealthCare, Biophysics, Fundamental, Investment, Pharmaceutical industry

Lorenz is a highly respected biopharmaceutical executive with extensive experience over the last 30 years in drug discovery, technology and innovation, business growth and financing strategy.

Key Points: 
  • Lorenz is a highly respected biopharmaceutical executive with extensive experience over the last 30 years in drug discovery, technology and innovation, business growth and financing strategy.
  • Lorenz has extensive global experience in pharmaceutical R&D, including positions as Vice President & Global Head at AstraZeneca and Executive Director at Novartis and Bayer Pharmaceuticals.
  • Keno Gutierrez, Chairman of the Board of FundaMental Pharma, commented: “We are excited to share that Lorenz, a seasoned and highly regarded industry leader, has joined our Board of Directors.
  • I am confident that Lorenz`s energy, conceptual guidance and reach will make a difference in advancing FundaMental Pharma`s key program to the next level.”

Conformation-X Therapeutics Bolts out of Stealth, Securing Over $13.5M in Funding to Propel Its Innovative Immune-Oncology Pipeline

Retrieved on: 
onsdag, april 3, 2024
Research, Venture Capital, Professional Services, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, TME, IL18BP, Patient, Neoplasm, Tumor microenvironment, Biology, Biophysics, Therapy, Cancer, Structural biology, Escape Room

Drawing inspiration from the fundamental role of protein conformations in disease biology and drug efficacy, Conformation-X applies unparalleled precision to developing novel immune checkpoint inhibitors.

Key Points: 
  • Drawing inspiration from the fundamental role of protein conformations in disease biology and drug efficacy, Conformation-X applies unparalleled precision to developing novel immune checkpoint inhibitors.
  • The company is creating a comprehensive portfolio of differentiated therapeutics addressing cancer mechanisms that have eluded existing treatments.
  • Dr. Munawar added, “We are committed to pioneering alternative therapeutic options for these patients by targeting novel biology and molecular pathways.
  • Our work highlights the strength of Conformation-X’s drug discovery platform,” said Dr. Stephen Weeks, Sr. Director of Structural Biology and Biophysics.

Atomwise Publishes Results from 318-Target Study Showcasing AtomNet AI Platform’s Ability to Discover Structurally Novel Chemical Matter

Retrieved on: 
tisdag, april 2, 2024
Research, Technology, Neurology, Health Technology, Biotechnology, Managed Care, Pharmaceutical, Health, Science, Artificial Intelligence, AIMS, Biochemistry, Disease, Executive, University, HTS, Patient, AI, Scientific Reports, OTUD7B, IND, PPM1D, Biology, Biophysics, Cancer, Pharmacokinetics, TYK2, Development, Probability, Artificial intelligence, Proteome, Pharmaceutical industry

Atomwise announced today results from the AIMS (Artificial Intelligence Molecular Screen) initiative that establish the AtomNet AI Platform as a viable alternative to high-throughput screening (HTS) and verify its ability to consistently discover structurally novel chemical matter.

Key Points: 
  • Atomwise announced today results from the AIMS (Artificial Intelligence Molecular Screen) initiative that establish the AtomNet AI Platform as a viable alternative to high-throughput screening (HTS) and verify its ability to consistently discover structurally novel chemical matter.
  • AtomNet also showed a remarkable ability to discover novel chemical matter, averaging over seven structurally distinct bioactive compounds per target.
  • Developed by Atomwise, AtomNet was the first deep neural network designed to predict the bioactivity of small molecules in structure-based drug discovery.
  • Our belief is structurally novel chemical matter increases the likelihood of developing first-in-class and best-in-class medicines that have the potential to transform patient care.